BAX (Ab-167) Antibody

What is BAX protein and why is it important in cellular research?

BAX (Bcl-2-associated X protein) is a critical pro-apoptotic protein that plays a central role in the mitochondrial apoptotic process. Under normal conditions, BAX exists largely in the cytosol due to constant retrotranslocation from mitochondria mediated by BCL2L1/Bcl-xL, which prevents accumulation of toxic BAX levels at the mitochondrial outer membrane (MOM) . During cellular stress, BAX undergoes conformational changes leading to its translocation to the mitochondrial membrane, triggering cytochrome c release and subsequent activation of CASP3, ultimately resulting in apoptosis .

BAX is essential for studying programmed cell death pathways, cancer biology, neurodegenerative diseases, and cellular responses to various stressors, making BAX antibodies valuable research tools for investigating these processes.

What is the specific epitope recognized by BAX (Ab-167) Antibody?

BAX (Ab-167) Antibody specifically recognizes a non-phosphorylated peptide epitope derived from human BAX around the phosphorylation site of threonine 167 (F-G-T(p)-P-T) . This region is significant because phosphorylation at T167 can regulate BAX function and its involvement in apoptotic pathways. The antibody's specificity for this region makes it valuable for distinguishing between different phosphorylation states of BAX and studying post-translational modifications that affect BAX activity.

What experimental applications is BAX (Ab-167) Antibody suitable for?

BAX (Ab-167) Antibody has been validated for multiple experimental applications:

The antibody demonstrates reactivity with human and mouse samples, making it suitable for comparative studies across these species . Researchers should perform appropriate controls and optimization steps for each specific application.

How should I design proper controls when using BAX (Ab-167) Antibody?

When designing experiments with BAX (Ab-167) Antibody, implement the following control strategies:

• Positive controls: Include cell lines known to express BAX (e.g., 293T cells or NIH/3T3 cells) as demonstrated in validated Western blot applications .

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at the same concentration)

  • Cells with BAX knockdown/knockout if available

• Peptide competition assay: Pre-incubate the antibody with the synthetic peptide immunogen to confirm specificity, as demonstrated with other phospho-specific BAX antibodies .

• Phosphorylation state controls:

  • Use phosphatase-treated samples to confirm phospho-specificity

  • Compare with non-phospho-specific BAX antibodies to assess total BAX levels

• Cross-reactivity assessment: Test the antibody against samples where BAX is complexed with inhibitory proteins like Bcl-2 or Bcl-XL to evaluate potential binding interference .

What are the optimal sample preparation methods for detecting BAX with Ab-167 Antibody?

For optimal detection of BAX using Ab-167 Antibody, follow these sample preparation guidelines:

For Western Blot:

• Lyse cells in a buffer containing phosphatase inhibitors to preserve phosphorylation states (critical for phospho-epitope studies)

• Include protease inhibitors to prevent degradation of BAX protein

• Maintain samples at 4°C during processing

• Use gentle detergents (0.1-1% Triton X-100 or NP-40) to preserve protein conformation

• When detecting mitochondrial-associated BAX, consider subcellular fractionation methods to separate cytosolic and mitochondrial fractions

For Immunofluorescence:

• Fix cells with 4% paraformaldehyde or methanol (methanol fixation has been validated for some BAX antibodies)

• Permeabilize with 0.1-0.5% Triton X-100 for adequate antibody penetration

• Block with 5% normal serum from the same species as the secondary antibody

• Include counterstains for mitochondria (e.g., MitoTracker) for colocalization studies

Buffer composition considerations:
The antibody is supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol . Ensure your experimental buffers are compatible with these components.

How should I optimize BAX (Ab-167) Antibody dilution for my specific experimental system?

Optimizing antibody dilution is critical for balancing signal strength with background. Follow this systematic approach:

• Initial titration experiment:

  • For Western blot: Test a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:3000) using positive control samples

  • For immunofluorescence: Test dilutions ranging from 1:100 to 1:500

• Signal-to-noise evaluation:

  • Assess specific signal intensity versus background at each dilution

  • Select the dilution that maximizes specific signal while minimizing background

• Sample-specific optimization:

  • Different cell types/tissues may require different optimal dilutions

  • Samples with low BAX expression may require higher antibody concentrations

• Incubation conditions optimization:

  • Test both room temperature (1-2 hours) and 4°C (overnight) incubations

  • Determine if gentle agitation improves staining uniformity

• Secondary antibody matching:

  • Ensure the secondary antibody (anti-rabbit IgG) is optimally diluted

  • Test different detection systems (HRP, fluorescent) if applicable

Document your optimization process methodically to ensure reproducibility across experiments.

How can I use BAX (Ab-167) Antibody to study BAX conformational changes during apoptosis?

BAX conformational changes represent a critical checkpoint in the apoptotic pathway. To investigate this process:

• Comparative immunostaining approach:

  • Use BAX (Ab-167) Antibody alongside conformation-specific antibodies like clone 6A7, which specifically recognizes the active conformation of BAX

  • Compare subcellular localization patterns using dual immunofluorescence

  • Monitor temporal changes during apoptosis induction

• Subcellular fractionation combined with Western blotting:

  • Separate cytosolic and mitochondrial fractions

  • Quantify BAX distribution and phosphorylation status in each fraction

  • Correlate with apoptotic markers like cleaved CASP3

• Immunoprecipitation strategies:

  • Use BAX (Ab-167) to immunoprecipitate BAX protein complexes

  • Analyze binding partners (e.g., other Bcl-2 family proteins) by Western blot

  • Compare BAX interaction profiles before and after apoptotic stimuli

• Advanced microscopy techniques:

  • Apply super-resolution microscopy to visualize BAX clustering at mitochondria

  • Use FRET (Fluorescence Resonance Energy Transfer) to detect BAX-BAX interactions or BAX-mitochondria associations

  • Implement live-cell imaging with compatible fluorescent tags to track BAX translocation in real-time

What are the critical factors to consider when interpreting BAX phosphorylation data using Ab-167 Antibody?

Interpreting BAX phosphorylation data requires careful consideration of several factors:

• Phosphorylation site specificity:

  • BAX (Ab-167) Antibody targets the region around threonine 167 (F-G-T(p)-P-T)

  • Understand that this specific phosphorylation site may be differentially regulated compared to other BAX phosphorylation sites

• Temporal dynamics:

  • Phosphorylation states can change rapidly during apoptosis

  • Design time-course experiments to capture transient phosphorylation events

  • Consider that dephosphorylation may be as important as phosphorylation in regulating BAX function

• Upstream kinase activity:

  • Different kinases may target T167 under different cellular conditions

  • Consider using kinase inhibitors to establish causality between specific kinase activity and BAX phosphorylation

• Integration with other BAX modifications:

  • Phosphorylation may influence other post-translational modifications of BAX

  • Consider how phosphorylation affects BAX conformation, oligomerization, and interactions with other proteins

• Technical considerations:

  • Phospho-epitopes can be sensitive to sample preparation methods

  • Phosphatase inhibitors must be present throughout sample processing

  • Consider parallel analysis with phospho-independent BAX antibodies to normalize for total BAX expression

How can BAX (Ab-167) Antibody be used in combination with other antibodies for comprehensive apoptosis pathway analysis?

A comprehensive analysis of apoptotic pathways requires a strategic multiplexed antibody approach:

• Multi-parameter flow cytometry panels:

  • Combine BAX (Ab-167) Antibody with antibodies against:

    • Other Bcl-2 family proteins (Bcl-2, Bcl-XL, Bak)

    • Activated caspases (CASP3, CASP9)

    • Mitochondrial integrity markers (cytochrome c)

    • Cell death indicators (Annexin V, propidium iodide)

  • Develop compensation protocols for spectral overlap when using multiple fluorophores

• Sequential immunoblotting strategy:

  • Design a sequential probing protocol that allows detection of multiple proteins from the same membrane

  • Use appropriate stripping and reprobing techniques that preserve epitope integrity

  • Example sequence: phospho-BAX → total BAX → cleaved CASP3 → cytochrome c → loading control

• Multiplex immunohistochemistry/immunofluorescence:

  • Employ techniques like tyramide signal amplification to enable detection of multiple antigens

  • Use primary antibodies from different host species to avoid cross-reactivity

  • Include subcellular compartment markers (mitochondria, nucleus) for colocalization analysis

• Antibody-based proximity assays:

  • Implement proximity ligation assays (PLA) to detect BAX interactions with other proteins

  • Use FRET or BRET techniques to monitor real-time protein associations

• Validation with functional assays:

  • Correlate antibody-based detection with functional assessments of apoptosis

  • Include mitochondrial membrane potential measurements

  • Assess DNA fragmentation and cellular morphological changes

What are the common causes of inconsistent results when using BAX (Ab-167) Antibody, and how can they be addressed?

When experiencing inconsistent results with BAX (Ab-167) Antibody, consider these common issues and solutions:

• Antibody degradation issues:

  • Problem: Repeated freeze-thaw cycles can degrade antibody quality

  • Solution: Aliquot the antibody upon receipt and store at -20°C or -80°C ; avoid repeated freezing

• Epitope masking:

  • Problem: Protein interactions or conformational changes may mask the T167 epitope

  • Solution: Optimize sample preparation with various lysis buffers; consider mild denaturing conditions

• Phosphorylation state variability:

  • Problem: Phosphorylation status changes rapidly during sample processing

  • Solution: Use phosphatase inhibitors consistently; process samples rapidly at 4°C

• Cross-reactivity concerns:

  • Problem: Potential cross-reactivity with similar epitopes in other proteins

  • Solution: Include appropriate negative controls; perform peptide competition assays

• Detection system limitations:

  • Problem: Secondary antibody or detection reagent inefficiency

  • Solution: Test alternative detection systems; ensure secondary antibody compatibility

• Sample-specific issues:

  • Problem: Different cell types may show variable BAX expression or accessibility

  • Solution: Adjust protein loading; optimize permeabilization for immunofluorescence

• Protocol inconsistencies:

  • Problem: Minor variations in protocol execution

  • Solution: Develop detailed standardized protocols; maintain consistent reagent lots

How can I distinguish between specific and non-specific signals when using BAX (Ab-167) Antibody?

Distinguishing specific from non-specific signals requires rigorous validation:

• Molecular weight verification:

  • Human BAX protein has a molecular weight of ~21 kDa

  • Verify that the primary band appears at the expected molecular weight

  • Document and investigate any additional bands systematically

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing peptide before application

  • Specific signals should be significantly reduced or eliminated

  • Persistent signals after competition suggest non-specific binding

• BAX knockdown/knockout validation:

  • Compare signal intensity between wild-type and BAX-depleted samples

  • Specific signals should be diminished proportionally to the reduction in BAX expression

  • Persistent signals in knockout samples indicate non-specific binding

• Signal pattern analysis in immunofluorescence:

  • BAX typically shows cytoplasmic staining with potential mitochondrial enrichment during apoptosis

  • Aberrant patterns (e.g., exclusively nuclear) may indicate non-specific binding

  • Compare with published BAX localization patterns

• Cross-validation with alternative antibodies:

  • Compare results with other validated BAX antibodies targeting different epitopes

  • Concordant results across different antibodies support specificity

• Secondary antibody-only controls:

  • Omit primary antibody while maintaining all other steps

  • Any signal indicates secondary antibody non-specific binding

What methodological approaches can resolve contradictory data when comparing results from BAX (Ab-167) Antibody with other BAX antibodies?

When facing contradictory results between different BAX antibodies, employ these reconciliation approaches:

• Epitope mapping comparison:

  • BAX (Ab-167) Antibody targets the region around T167

  • Clone 6A7 recognizes an N-terminal epitope (aa 12-24) exposed only in the active conformation

  • Other antibodies may target different regions or conformations

  • Differences may reflect legitimate biological variance in epitope accessibility

• Antibody validation hierarchy:

  • Implement a systematic validation workflow using multiple techniques:

    • Western blot + immunoprecipitation + mass spectrometry

    • Genetic knockout validation

    • Cross-species conservation analysis

  • Establish confidence rankings for different antibodies based on validation depth

• Context-dependent epitope accessibility:

  • Different fixation methods may preserve different epitopes

  • Compare paraformaldehyde vs. methanol fixation

  • Test different permeabilization conditions

  • Evaluate native vs. denaturing conditions for each antibody

• Quantitative comparative analysis:

  • Perform side-by-side titration curves with different antibodies

  • Calculate relative affinities and dynamic ranges

  • Normalize signals to recombinant BAX standards when possible

• Triangulation with functional data:

  • Correlate antibody signals with functional readouts of BAX activity

  • Measure mitochondrial outer membrane permeabilization

  • Assess cytochrome c release and caspase activation

  • Determine which antibody best predicts functional outcomes

How can BAX (Ab-167) Antibody be used to investigate the role of T167 phosphorylation in regulating BAX-mediated apoptosis?

To investigate the specific role of T167 phosphorylation in BAX-mediated apoptosis:

• Phosphorylation site mutation studies:

  • Compare wild-type BAX with T167A (phospho-null) and T167D/E (phospho-mimetic) mutants

  • Use BAX (Ab-167) Antibody to confirm loss of the epitope in mutants

  • Correlate phosphorylation status with subcellular localization and apoptotic activity

• Kinase/phosphatase identification:

  • Use kinase and phosphatase inhibitor panels to identify enzymes regulating T167 phosphorylation

  • Perform in vitro kinase assays to confirm direct phosphorylation

  • Use siRNA/shRNA knockdowns of candidate kinases to validate in cellular contexts

• Temporal dynamics during apoptosis:

  • Track T167 phosphorylation timing relative to:

    • BAX conformational change (using conformation-specific antibodies)

    • Mitochondrial translocation

    • Cytochrome c release

    • Caspase activation

  • Determine whether phosphorylation is a cause or consequence of BAX activation

• Structural and biophysical studies:

  • Use antibody-based purification of differentially phosphorylated BAX

  • Perform structural analyses (X-ray crystallography, cryo-EM) to determine how phosphorylation affects BAX conformation

  • Employ in vitro liposome permeabilization assays to assess functional consequences

• Integration with other BAX modifications:

  • Investigate potential crosstalk between T167 phosphorylation and other BAX modifications

  • Examine how T167 phosphorylation affects BAX ubiquitination, acetylation, or other phosphorylation events

What advanced imaging techniques can be combined with BAX (Ab-167) Antibody to elucidate the spatiotemporal dynamics of BAX during apoptosis?

Advanced imaging approaches can provide unprecedented insights into BAX dynamics:

• Super-resolution microscopy techniques:

  • STED (Stimulated Emission Depletion) microscopy for nanoscale resolution of BAX clusters

  • STORM/PALM for single-molecule localization of BAX oligomers

  • SIM (Structured Illumination Microscopy) for improved resolution of BAX-mitochondria interactions

  • Combine with appropriate secondary antibodies or direct fluorophore conjugation

• Live-cell imaging strategies:

  • Develop non-disruptive cell-permeable antibody derivatives

  • Use nanobody-based approaches for live-cell detection

  • Correlate with fluorescently-tagged BAX for validation

  • Implement microfluidic systems for controlled apoptosis induction during imaging

• Multi-modal imaging:

  • Combine fluorescence microscopy with electron microscopy

  • Use methods like CLEM (Correlative Light and Electron Microscopy)

  • Employ immunogold labeling for EM localization of BAX

  • Integrate with appropriate immunofluorescence controls and optimization

• Functional imaging integration:

  • Simultaneously monitor:

    • BAX localization/phosphorylation (using Ab-167)

    • Mitochondrial membrane potential (using potentiometric dyes)

    • Calcium fluxes (using calcium indicators)

    • Caspase activation (using FRET-based reporters)

• Quantitative image analysis:

  • Develop algorithms for automatic detection of BAX translocation

  • Implement machine learning approaches for pattern recognition

  • Quantify colocalization coefficients with mitochondrial markers

  • Perform single-cell analysis to capture heterogeneity in responses

How can antibody modeling and in silico approaches be integrated with BAX (Ab-167) Antibody research to advance our understanding of BAX structure-function relationships?

Integrating computational approaches with experimental antibody research can provide deeper mechanistic insights:

• Antibody-epitope interaction modeling:

  • Apply antibody modeling techniques to predict BAX (Ab-167) Antibody binding to its epitope

  • Use established antibody modeling frameworks to generate structural models

  • Predict how phosphorylation of T167 affects antibody recognition

  • Guide mutation studies to validate computational predictions

• Molecular dynamics simulations:

  • Simulate the effects of T167 phosphorylation on BAX conformation

  • Model potential allosteric effects on distant BAX regions

  • Investigate how phosphorylation might affect BAX-membrane interactions

  • Generate testable hypotheses for experimental validation

• Integrative structural biology:

  • Combine antibody epitope mapping data with:

    • X-ray crystallography of BAX fragments

    • NMR data on BAX conformational dynamics

    • Hydrogen-deuterium exchange mass spectrometry

  • Build comprehensive structural models of BAX in different activation states

• Machine learning approaches:

  • Train algorithms on antibody binding data to predict epitope accessibility

  • Apply techniques similar to those used in COVID-19 antibody research

  • Develop predictive models for BAX conformational changes

  • Use AI to design next-generation BAX antibodies with enhanced specificity

• Systems biology integration:

  • Model BAX within the context of the complete apoptotic network

  • Predict how T167 phosphorylation affects network dynamics

  • Simulate the effects of targeted BAX modifications on cell fate decisions

  • Validate predictions with targeted experiments using BAX (Ab-167) Antibody

How can BAX (Ab-167) Antibody be adapted for use in emerging single-cell technologies to study apoptosis heterogeneity?

Adapting BAX antibodies for single-cell technologies offers new insights into cellular heterogeneity:

• Single-cell proteomics applications:

  • Optimize BAX (Ab-167) Antibody for mass cytometry (CyTOF)

  • Develop metal-conjugated versions for multiplexed detection

  • Integrate with single-cell Western blotting platforms

  • Implement proximity extension assays for ultrasensitive detection

• Spatial proteomics integration:

  • Adapt for technologies like CODEX or multiplexed ion beam imaging

  • Optimize for Imaging Mass Cytometry applications

  • Develop protocols for highly multiplexed immunofluorescence

  • Integrate with spatial transcriptomics for multi-omic analysis

• Microfluidic-based approaches:

  • Design antibody-based microfluidic capture systems

  • Develop protocols for single-cell antibody barcoding

  • Optimize for droplet-based single-cell protein detection

  • Create integrated systems for correlating BAX status with cellular outcomes

• Custom conjugation strategies:

  • Develop site-specific conjugation methods to preserve epitope binding

  • Create bifunctional reagents for simultaneous capture and detection

  • Optimize antibody fragments (Fab, scFv) for improved penetration

  • Engineer click chemistry-compatible variants for modular applications

• Validation frameworks:

  • Establish ground-truth datasets using cell mixtures with known BAX states

  • Develop computational pipelines for handling single-cell antibody data

  • Create reference standards for cross-platform normalization

  • Implement quality control metrics specific to single-cell applications

What are the methodological considerations for using BAX (Ab-167) Antibody in studying the intersection of apoptosis and other cellular processes like autophagy or necroptosis?

Investigating the crosstalk between apoptosis and other cell death/survival pathways requires specialized methodological considerations:

• Multi-pathway protein detection strategies:

  • Design multiplexed antibody panels targeting:

    • BAX and apoptosis markers (using BAX Ab-167)

    • Autophagy proteins (LC3, p62, Beclin-1)

    • Necroptosis mediators (RIPK1, RIPK3, MLKL)

    • Common regulators (e.g., post-translational modifiers)

  • Develop sequential blotting protocols preserving epitope integrity across multiple stripping cycles

• Pathway modulation approaches:

  • Establish protocols using specific pathway inhibitors:

    • Apoptosis: Z-VAD-FMK (pan-caspase inhibitor)

    • Autophagy: Bafilomycin A1, 3-methyladenine

    • Necroptosis: Necrostatin-1

  • Monitor BAX phosphorylation status during pathway switching

  • Compare epitope accessibility under different cell death modes

• Time-resolved analysis:

  • Develop synchronized cell systems for temporally controlled pathway induction

  • Implement pulse-chase approaches to track protein dynamics across pathways

  • Use time-course immunoprecipitation to identify transient BAX interaction partners

  • Establish critical time points for multi-pathway analysis

• Subcellular compartment-specific analysis:

  • Optimize fractionation protocols preserving phosphorylation status

  • Track BAX translocation between compartments during pathway crosstalk

  • Develop protocols for organelle-specific immunoprecipitation

  • Implement proximity labeling approaches to map compartment-specific interactomes

• Genetic modification strategies:

  • Design cellular systems with inducible pathway components

  • Create reporter cell lines expressing fluorescent BAX fusion proteins

  • Implement CRISPR-based screening to identify pathway intersection points

  • Validate findings using BAX (Ab-167) Antibody in modified genetic backgrounds

How might new antibody engineering approaches like AI-guided design be applied to develop next-generation BAX antibodies with enhanced specificity and functionality?

Emerging antibody engineering technologies offer opportunities for developing advanced BAX-targeting reagents:

• AI-guided antibody design strategies:

  • Apply deep learning models similar to the Pre-trained Antibody generative Large Language Model (PALM-H3) to design optimized BAX antibodies

  • Train algorithms on existing BAX antibody performance data

  • Predict modifications to enhance specificity for particular BAX conformations

  • Develop antibodies targeting functionally significant epitopes beyond T167

• Rational structure-based engineering:

  • Use antibody modeling frameworks to predict binding characteristics

  • Apply computational alanine scanning to identify critical binding residues

  • Design humanized versions with preserved epitope specificity

  • Engineer variants with enhanced stability and reduced aggregation tendency

• Novel antibody format development:

  • Create bispecific antibodies targeting BAX and interacting proteins simultaneously

  • Develop intrabodies for live-cell applications

  • Engineer antibody fragments (Fab, scFv, nanobodies) for improved tissue penetration

  • Create conditionally active antibodies that recognize specific BAX conformations

• Functional antibody enhancement:

  • Develop antibodies that not only bind but modulate BAX activity

  • Engineer allosteric inhibitors or activators of BAX function

  • Create phosphorylation-specific antibodies with enhanced discrimination

  • Develop antibodies with tailored binding kinetics for specific applications

• High-throughput screening approaches:

  • Implement display technologies (phage, yeast, ribosome) for affinity maturation

  • Develop selection strategies specifically for conformation-specific antibodies

  • Create screening assays mimicking physiological BAX environments

  • Use proteome-wide autoantibody screening approaches to identify novel BAX epitopes